Clinical trial NCT03817424: A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Official title: A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Systemic Lupus Erythematosus
Cutaneous Lupus Erythematosus
Sjogren's Syndrome
Systemic Sclerosis
Polymyositis
Dermatomyositis
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2019-01-25
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis.

Detailed description: This study will have 3 periods: screening, treatment period, and extended follow-up. The screening period is 28 days. A total of 32 participants will be enrolled in 3 cohorts with 8 participants in Cohort 1, and 12 participants each in Cohorts 2 and 3. In Cohort 1, participants will be randomized in a 3:1 ratio to receive VIB7734 or matching placebo by injection every 4 weeks (q4w) for a total of 3 doses on Days 1, 29, and 57. In Cohorts 2 and 3, participants diagnosed with lupus only will be randomized in a 2:1 ratio to receive VIB7734 or matching placebo by injection q4w for 3 doses on Days 1, 29, and 57. Participants will be followed until at least Day 141. After the Day 141 visit, participants will exit the study if participants meets adequate plasmacytoid dendritic cells (pDCs). If an adequate pDC level does not meet at Day 141 visit, the participant will continue the follow-up for pDC repletion until they meet the protocol defined adequate pDC level or Day 337 visit has been reached.

Study acquired from Horizon in 2024. Originally Viela Bio was the sponsor.

Eligibility criteria: Inclusion Criteria:

* Participants aged 18 through 75 years at the time of screening
* Participants with at least one of the following diagnoses:

  1. Systemic Lupus Erythematosus
  2. Cutaneous lupus erythematosus, including acute CLE, subacute CLE, and discoid lupus erythematosus
  3. Sjogren's syndrome (for Cohort 1 only)
  4. Systemic sclerosis (for Cohort 1 only)
  5. Probable or definite polymyositis (for Cohort 1 only)
  6. Probable or definite dermatomyositis (for Cohort 1 only)
* For Cohorts 2 and 3 only: Participants with CLASI activity score greater than or equal to (\>=) 8 at both Visits 1 (screening) and 2 (baseline)
* For Cohorts 2 and 3 only: a skin lesion amenable to punch skin biopsy and willingness of the participant to undergo skin biopsy at two time points
* For Cohorts 2 and 3 only: photographs of skin lesions must be submitted for review to confirm the diagnosis of SLE or CLE with active skin lesions confirmation of the diagnosis by the central reviewer must be received prior to randomization
* Females of childbearing potential and nonsterilized males who are ready to use protocol defined contraception methods

Exclusion Criteria:

* Severe manifestations of the diseases under study that could impact the participant safety
* Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection, splenectomy, or any underlying condition that predisposes the participant to infection
* At screening, have adequate central laboratory test results: aspartate transaminase greater than (\>) 2.5 x upper limit of normal (ULN); alanine transaminase \>2.5 x ULN; total bilirubin 1.5 x ULN; total immunoglobulin \< 500 gram/decilitre; neutrophil count less than (\<) 1,000/μL; platelet count \< 85,000/μL; haemoglobin \< 10 g/dL; glycosylated haemoglobin \> 8 percent (%); total lymphocyte count \< 300 cells/mm\^3; glomerular filtration rate \< 50 mL/min/1.73 m\^2; plasmacytoid dendritic cells (pDC) level \< 0.02% of peripheral blood mononuclear cells (PBMCs)
* Positive test for chronic hepatitis B infection at screening and for hepatitis C virus antibody
* History of or active tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening; a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection per central laboratory; cancer; clinically significant cardiac disease
* Herpes zoster infection within 3 months before randomization and/or any severe herpes virus family infection at any time prior to randomization
* Any acute illness or evidence of clinically significant active infection, such as fever \>= 38.0 degrees Celsius (\>= 100.5 degrees Fahrenheit) at screening (Visit 1) or Day 1 (Visit 2)
* Cohorts 2 and 3 only: use of Group 1 (super-high potency) or Group 2 (high potency) topical corticosteroids
* Receipt of a live-attenuated vaccine within 4 weeks prior to Day 1
* Cohorts 2 and 3 only: have received changing doses of mycophenolate mofetil, methotrexate, leflunomide, azathioprine, or non-steroidal topical immunosuppressants within 28 days before study Day 1 or changing doses of oral or topical corticosteroids within 14 days before study Day 1

Primary outcomes:
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
timeFrame: Day 1 up to Day 337
measure: Number of Participants With Adverse Events of Special Interest (AESIs)
timeFrame: Day 1 up to Day 337
measure: Number of Participants With Laboratory Abnormalities Reported as TEAEs
timeFrame: Day 1 up to Day 337
measure: Number of Participants With Vital Sign Abnormalities Reported as TEAEs
timeFrame: Day 1 up to Day 337
measure: Number of Participants With 12-Lead Electrocardiogram Abnormalities Reported as TEAEs
timeFrame: Day 1 up to Day 337
Secondary outcomes:
measure: Maximum Observed Serum Concentration (Cmax) of VIB7734 Maximum Observed Serum Concentration (Cmax) of VIB7734
timeFrame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253
measure: Area Under the Concentration-time Curve (AUC) of VIB7734
timeFrame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253
measure: Systemic Clearance (CL) of VIB7734
timeFrame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253
measure: Terminal Half-life (t1/2) of VIB7734
timeFrame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253
measure: Number of Participants With Positive Anti-Drug Antibodies of VIB7734
timeFrame: Day 1 up to Day 309
measure: Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score (Cohorts 2 and 3)
timeFrame: Day 1 up to Day 253
measure: Blood Levels of pDCs
timeFrame: Day 1 up to Day 337
Other outcomes:
Locations:
city: Anniston
country: United States
facility: Viela Bio Investigative Site
state: Alabama
city: Birmingham
country: United States
facility: Viela Bio Investigative Site
state: Alabama
city: Los Angeles
country: United States
facility: Viela Bio Investigative Site
state: California
city: Upland
country: United States
facility: Viela Bio Investigative Site
state: California
city: Danbury
country: United States
facility: Viela Bio Investigative Site
state: Connecticut
city: Fort Lauderdale
country: United States
facility: Viela Bio Investigative Site
state: Florida
city: Hialeah
country: United States
facility: Viela Bio Investigative Site
state: Florida
city: Jacksonville
country: United States
facility: Viela Bio Investigative Site
state: Florida
city: Miami Lakes
country: United States
facility: Viela Bio Investigative Site
state: Florida
city: Saint Petersburg
country: United States
facility: Viela Bio Investigative Site
state: Florida
city: Lawrenceville
country: United States
facility: Viela Bio Investigative Site
state: Georgia
city: Great Neck
country: United States
facility: Viela Bio Investigative Site
state: New York
city: Charlotte
country: United States
facility: Viela Bio Investigative Site
state: North Carolina
city: Durham
country: United States
facility: Viela Bio Investigative Site
state: North Carolina
city: Duncansville
country: United States
facility: Viela Bio Investigative Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: Viela Bio Investigative Site
state: Pennsylvania
city: Memphis
country: United States
facility: Viela Bio Investigative Site
state: Tennessee
city: Allen
country: United States
facility: Viela Bio Investigative Site
state: Texas
city: Mesquite
country: United States
facility: Viela Bio Investigative Site
state: Texas
city: Białystok
country: Poland
facility: Viela Bio Investigative Site
city: Bydgoszcz
country: Poland
facility: Viela Bio Investigative Site
city: Kraków
country: Poland
facility: Viela Bio Investigative Site
city: Poznań
country: Poland
facility: Viela Bio Investigative Site
city: Rzeszów
country: Poland
facility: Viela Bio Investigative Site
city: Warsaw
country: Poland
facility: Viela Bio Investigative Site
city: Wrocław
country: Poland
facility: Viela Bio Investigative Site
city: Barcelona
country: Spain
facility: Viela Bio Investigative Site
city: Bilbao
country: Spain
facility: Viela Bio Investigative Site
city: Madrid
country: Spain
facility: Viela Bio Investigative Site
city: Sevilla
country: Spain
facility: Viela Bio Investigative Site
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: